Keywords
Everolimus
Calcineurin inhibitors
Chronic graft nephropathy
Nephrotoxicity (MeSHsource).
How to Cite
Abstract
Introduction: Graft survival has remained stable in the long term, without significant increase in recent years. Among the main causes of renal graft loss after the first year are death with functioning kidney graft from cardiovascular, infectious and neoplastic causes, and chronic graft injury for immunological and non-immunological causes. This has been attributed to the chronic use of calcineurin inhibitors (CNI), increased cardiovascular risk, the incidence of certain infections and increased incidence of post-transplant malignancies. Also, reports show the increased frequency of histological lesions related to nephrotoxicity caused by these drugs. The switch from CNI to mTOR inhibitors may decrease some of these effects in the long term. We conducted a retrospective study of conversion to mTOR inhibitors in patients with a CNI-based
scheme.
Materials and methods: A retrospective single-center case study was conducted, including renal transplantation patients with more than 6 months of transplantation, who were switched to everolimus, after an abrupt withdrawal of calcineurin inhibitor with a previous biopsy of the renal graft. Patients with evidence in the biopsy of changes of acute rejection, glomerular disease or relapse of acute tubular necrosis were excluded. Similarly, patients with proteinuria over 1 g in 24 hours and patients with clinical acute rejection within 3 months prior to conversion were excluded. A total of 40 patients were included, monitoring of variables such as glomerular filtration rate, proteinuria, lipids, use of antihypertensive drugs and adverse effects was performed after conversion until Day 720.
Results: The results, after 720 days of monitoring, show an increased glomerular filtration rate in 65% of the patients and a decrease in 30% of them. The proteinuria increased with respect to the pre-conversion values in all the patients, however proteinuria >1 g was present in 6 of the 40 patients after the same monitoring time. Of the 6 patients with proteinuria, 5 patients had more than 5 years of transplantation and moderate to severe interstitial fibrosis in the pre-conversion biopsy, which would be linked to the increase in proteinuria. The incidence of post-conversion acute rejection was 5%. The conversion tolerance was adequate, with a low frequency of adverse events that could lead to discontinuance of therapy.
Conclusion: Late conversion to everolimus in patients with kidney transplant from a CNI-based scheme is safe, improves renal function without a significant increase in the degree of proteinuria, associated with pre-conversion biopsies evidencing no significant degrees of interstitial chronicity. The tolerance to the scheme is appropriate and the frequency of acute rejection was not significantly increased.
References
2. Bennet WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther. 1996;34:515.
3. Myers BD, Newton L. Cyclosporine induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol. 1991;2(Suppl.1):45
4. Pascual M, Swinford RD, Ingelfinger JR, Williams WW, Cosimi AB, Tolkoff-Rubin N. Chronic rejection and chronic cyclosporine toxicity in renal allografts. Immunol Today. 1998;19:514.
5. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2 year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus vs cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998;66:1736.
6. Nankivell BJ, Borrows RJ, Fung CL, O’Conell PJ. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557.
7. Morris PJ, Chapman JR, Allen RD, Ting A, Thompson JF, Dunill MS, et al. Cyclosporine conversion versus conventional immunosuppression: long term follow up and histological evaluation. Lancet 1987;1:586.
8. Morris PJ, French ME, Dunill MS, Hunnisett G, Ting A, Thompson JF, et al. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983;36:273.
9. MacPhee IA, Bradley JA, Briggs JD, Juno BJ, MacPherson SG, McMillan MA, et al. Long term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 1998;66:1186.
10. Ducloux D, Fournier V, Bresson Vautrin C, Rebibou JM, Billerey C, Saint Hillier Y, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine associated nephrotoxicity: a preliminary report. Transplantation 1998;66:1186.
11. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, PaulLC, van der Woude FJ, et al. Open randomized trial comparing early withdrawal of either cyclosporine or ycophenolate mofetil in stable renal transplant recipients initially
treated with a triple drug regimen. J Am Soc Nephrol 2002;13:536.
12. Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004;24:379.
13. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365.
14. Afzali B, Shah S, Chowdhury P, O;sullivan H, Taylor J, Goldsmith D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005;79:304.
15. Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 1995;345:610.
16. Heim-Duthoy KL, Chitwood KK, Tortorice KL, Massy ZA, KasiSke BL. Elective cyclosporine withdrawal 1 year after renal transplantation. Am J Kidney Dis 1994;24:846.
17. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mas BJ, Ijzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil following by dose reduction. Transplantation 2000; 70:143.
18. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006;6:514.
19. Grinyo JM, Cruzado JM, Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006;6:1991.
20. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004;4:1776.
21. Ekberg H, Tedesco–Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N England J Med 2007;357:2562.
22. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735.
23. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after idney transplantation. JAMA 2006;296:2823.
24. Sturgill TW, Hall MN. Holding back TOR advances mitosis. Nat Cell Biol 2007;9:1221.
25. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471.
26. Joannides R, Etienne I, Iacob M, Hurault de Ligny B, Barbier S, Bellien J, et al. Comparative effects of sirolimus and cyclosporine on conduit arteries endothelial function in renal transplant recipients. Transplant Int 2010;23(11):1135.
27. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to Everolimus: impact on pulse wave velocity in stable de novo renal allograft recipients. J Hypertens 2008;26(11):2213.
28. Mathew T, Kreis H, Friend P. Two years incidence of malignancy in sirolimus treated renal transplant: results from five multicenter studies. Clin Transplant 2004;18:446.
29. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, et al. Low incidence of malignancy among sirolimus/cyclosporine treated renal transplant recipients. Transplantation 2005;80:749.
30. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-months efficacy and afety results from the CONVERT trial. Transplantation 2009;87(2):233.
31. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006;82(9):1153.
32. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869.
33. Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755.
34. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517.
35. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005;80(11):1578.
36. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus based calcineurin inhibitor free regimen in recipients of de novo kidney transplants: an open label randomized controlled trial. Lancet 2011;377(9768):837.
37. Sánchez Fructuoso A, Ruiz JC, Hernández J, Sánchez Plumed J, Fernández A, Pastor Rodríguez A, et al. Early Everolimus Introduction and Calcineurin Inhibitor Withdrawal in Renal Transplant Patients: A Multicenter, Randomized, Open-Label Study (The ERIC Study). Abstract [1647] American Transplant Congress 2010.
38. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosupressive agent SDZ RAD, a rapamycin derivate. Exp Nephrol 2000;8(1):52.
39. Buchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, et al. Sirolimus vs cyclosporine in kidney recipients receiving thymoglobulin, micophenolate mofetil and 6 month course of steroids. Am J Transplant 2007;7:2522.
40. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, et al. Comparison of sirolimus based calcineurin inhibitor sparing and calcineurin inhibitor free regimens in cadaveric renal transplantation. Transplantation 2004;77(8):1228.
41. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74(8):1070.
42. Hamdy AF, EL Agroudy AE, Bakr MA, Mostafa A, El Baz M, EI Shahawy el M, et al. Comparison of sirolimus with low dose tacrolimus versus sirolimus based calcineurin inhibitor free regimen in live donor renal transplant recipients. Am J Transplant 2005;5:2531.
43. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89(12):1511.
44. Letavernier E, Legendre C. mTOR inhibitors induced proteinuria: mechanisms, significance, and managment. Transplant Rev (Orlando) 2008;22:125.
45. Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. Study of Anemia After Late Introduction of Everolimus in the Immunosuppressive Treatment
of Renal Transplant Patients. Transplantation proceedings 2007;39(7):2242.
46. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41(4 Suppl 3):I–IV, 1.
47. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Co Cardiology 2004;44(3):720.
48. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of flfluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 2003;361:2024.